 HAYWARD, Calif.--BUSINESS WIRE--Arcus Biosciences, Inc. NYSE:RCUS, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, at the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity measured by overall response rate; ORR when given as an initial treatment first-line to people with metastatic, PD-L150 non-small cell lung c 